PMID- 23945304
OWN - NLM
STAT- MEDLINE
DCOM- 20140501
LR  - 20130815
IS  - 0578-1426 (Print)
IS  - 0578-1426 (Linking)
VI  - 52
IP  - 5
DP  - 2013 May
TI  - [The efficacy and safety of unmanipulated haploidentical peripheral blood stem 
      cell transplantation on hematologic diseases].
PG  - 390-4
AB  - OBJECTIVE: To evaluate the efficacy and safety of unmanipulated haploidentical 
      allogeneic peripheral blood stem cells transplantation (PBSCT) on hematologic 
      diseases. METHODS: Patients who underwent unmanipulated 
      HLA-mismatched/haploidentical PBSCT from July 2007 to December 2011 were 
      investigated retrospectively. RESULT: Forty-nine patients with hematologic 
      diseases underwent unmanipulated human leukocyte antigen 
      (HLA)-mismatched/haploidentical PBSCT with myeloablative conditioning. All 
      patients were mismatched at the allele level for HLA-A, HLA-B, HLA-Cw, HLA-DRB1 
      and HLA-DQ1. Fifteen patients were mismatched in 5 loci, 11 patients in 4 loci, 7 
      patients in 3 loci, 5 patients in 2 loci, and 11 patients in 1 locus. The median 
      numbers of mononuclear cells and CD(3)(4)(+) cells infused at transplantation were 
      10.01(7.05-25.34) x 10(8)/kg and 4.51 (2.01-11.47) x 10(6)/kg, respectively. Patients 
      achieved myeloid and platelet engraftment at a median of 14 (10-25) days and 22 
      (10-135) days, respectively. The cumulative incidence of acute graft versus host 
      disease (aGVHD) on day 100 was (61.6 +/- 7.3)%, and the 2-year cumulative incidence 
      of chronic graft versus host disease (cGVHD) was (42.6 +/- 8.5)%. One hundred-day 
      transplantation related mortality (TRM) rate and 2-year cumulative TRM rate were 
      (14.7 +/- 5.1)% and (30.9 +/- 8.8)%, respectively. The 2-year cumulative incidence 
      estimate of relapse was (25.4 +/- 7.0)%. The 2-year cumulative overall survival 
      rate was (58.1 +/- 8.8)% and 2-year disease-free survival rate was (53.9 +/- 8.4)% 
      with an 11.5-months median follow-up. CONCLUSION: Unmanipulated PBSCT is a 
      promising protocol for patients with hematologic diseases in 
      HLA-mismatched/haploidentical transplant settings.
FAU - Huang, Wen-rong
AU  - Huang WR
AD  - Department of Hematology, Chinese PLA General Hospital, Beijing 100853, China.
FAU - Li, Hong-hua
AU  - Li HH
FAU - Jin, Xiang-shu
AU  - Jin XS
FAU - Wang, Shu-hong
AU  - Wang SH
FAU - Bo, Jian
AU  - Bo J
FAU - Zhao, Yu
AU  - Zhao Y
FAU - Jing, Yu
AU  - Jing Y
FAU - Zhu, Hai-yan
AU  - Zhu HY
FAU - Dou, Li-ping
AU  - Dou LP
FAU - Jia, Bo-jun
AU  - Jia BJ
FAU - Wang, Qun-shun
AU  - Wang QS
FAU - Gao, Chun-ji
AU  - Gao CJ
FAU - Yu, Li
AU  - Yu L
LA  - chi
PT  - English Abstract
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - China
TA  - Zhonghua Nei Ke Za Zhi
JT  - Zhonghua nei ke za zhi
JID - 16210490R
RN  - 0 (HLA Antigens)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Child
MH  - Child, Preschool
MH  - Female
MH  - HLA Antigens/immunology
MH  - Haploidy
MH  - Hematologic Diseases/immunology/*surgery
MH  - *Histocompatibility
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Peripheral Blood Stem Cell Transplantation/*methods
MH  - Retrospective Studies
MH  - Transplantation Conditioning
MH  - Treatment Outcome
MH  - Young Adult
EDAT- 2013/08/16 06:00
MHDA- 2014/05/03 06:00
CRDT- 2013/08/16 06:00
PHST- 2013/08/16 06:00 [entrez]
PHST- 2013/08/16 06:00 [pubmed]
PHST- 2014/05/03 06:00 [medline]
PST - ppublish
SO  - Zhonghua Nei Ke Za Zhi. 2013 May;52(5):390-4.